Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00267553
Recruitment Status : Terminated (This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint)
First Posted : December 21, 2005
Last Update Posted : September 10, 2007
Information provided by:
Intarcia Therapeutics

Brief Summary:
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.

Condition or disease Intervention/treatment Phase
Breast Neoplasms Neoplasms, Hormone-Dependent Drug: Atamestane Drug: toremifene Drug: letrozole Phase 3

Detailed Description:
Aromatase is an enzyme expressed in tissues such as muscle and fat in postmenopausal women. These non-ovarian tissues become the dominant sources of estrogen in postmenopausal women. Breast cancer cells are often very dependent on estrogens to continue to grow. Atamestane blocks the formation of estrogens from androgenic precursors in the body via the aromatase enzyme. Toremifene blocks circulating and intracellular estrogens from stimulating estrogen receptors in breast cancer cells. The goal of therapy with atamestane, an aromatase inhibitor, in combination with the estrogen receptor antagonist, toremifene, is to achieve complete suppression of estrogen stimulation of breast cancer cells. This study is designed to determine whether combined hormonal therapy will lengthen the time to disease progression and the survival time for subjects with advanced breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Study Start Date : November 2005
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. In conjunction with the data from Biomed 777-CLP-29, compare the time to progression (TTP) in the atamestane plus toremifene arm to the TTP in the letrozole plus placebo arm

Secondary Outcome Measures :
  1. In conjunction with the data from Biomed 777-CLP-29, obtain safety, survival and time to treatment failure (TTF) data for both arms in this continuation study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • To be eligible to receive continued treatment, subjects must remain eligible to receive study drug at the time of their last Biomed 777-CLP-29 visit
  • To continue on survival follow-up, subjects must be in survival follow-up in study Biomed 777-CLP-29
  • Written informed consent obtained for subjects who continue study drug treatment

Exclusion Criteria:

  • Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason
  • Subjects for whom the investigator considers study participation is no longer in the best interest of those subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00267553

Layout table for location information
United States, California
Greenbrae, California, United States
United States, Michigan
St. Joseph, Michigan, United States
United States, Missouri
Kansas City, Missouri, United States
United States, Texas
Houston, Texas, United States
United States, Virginia
Norfolk, Virginia, United States
United States, Washington
Lacey, Washington, United States
Canada, Ontario
Ottawa, Ontario, Canada
Thunder Bay, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Russian Federation
Arkhangelsk, Russian Federation
Kazan, Russian Federation
Krasnodar, Russian Federation
Leningrad Region, Russian Federation
Lipetsk, Russian Federation
Moscow, Russian Federation
Murmansk, Russian Federation
N. Novgorod, Russian Federation
Novgorod, Russian Federation
Novosibirsk, Russian Federation
Obninsk, Russian Federation
Ryazan, Russian Federation
Samara, Russian Federation
St. Petersburg, Russian Federation
Stavropol, Russian Federation
Tomsk, Russian Federation
Voronezh, Russian Federation
Dnepropetrovsk, Ukraine
Donetsk, Ukraine
Ivano-Frankovsk, Ukraine
Kharkov, Ukraine
Kiev, Ukraine
Krivoy Rog, Ukraine
Lviv, Ukraine
Odessa, Ukraine
Uzhgorod, Ukraine
Sponsors and Collaborators
Intarcia Therapeutics
Layout table for investigator information
Study Director: Peter Langecker, MD, PhD Intarcia Therapeutics

Layout table for additonal information Identifier: NCT00267553    
Other Study ID Numbers: Biomed 777-CLP-32
First Posted: December 21, 2005    Key Record Dates
Last Update Posted: September 10, 2007
Last Verified: September 2007
Keywords provided by Intarcia Therapeutics:
Breast neoplasms
Combined hormonal therapy
Complete estrogen blockade
Ductal breast carcinoma
Estrogen blocker
First line therapy
Lobular breast carcinoma
Locally advanced breast cancer
Locally recurrent breast cancer
Maximal estrogen inhibition
Metastatic breast cancer
Neoplasms, Hormone-dependent
Stage IIIA breast cancer
Stage IIIB breast cancer
Stage IV breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms, Hormone-Dependent
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents